
TRIO Pharmaceuticals
$6.0M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
TRIO Pharmaceuticals is currently valued at $17.0M as of November 7, 2024. The company has raised a total of $8.5M in funding.
Capital Efficiency
With a capital efficiency ratio of 2.00x, TRIO Pharmaceuticals has achieved a valuation that is 2.00 times the total capital raised. This metric indicates moderate capital efficiency.
Investment Perspective
TRIO Pharmaceuticals's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is TRIO Pharmaceuticals Worth in 2025?
As of 2025, TRIO Pharmaceuticals is valued at $17.0M, based on the company's Later Stage VC funding round in November 7, 2024. This valuation positions TRIO Pharmaceuticals as one of the leading private companies in the sector.
TRIO Pharmaceuticals Valuation History
TRIO Pharmaceuticals's funding history demonstrates steady growth and investor confidence.
How TRIO Pharmaceuticals Valuation is Determined
Private company valuations like TRIO Pharmaceuticals's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
TRIO Pharmaceuticals Valuation FAQs
Is TRIO Pharmaceuticals profitable?
TRIO Pharmaceuticals has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does TRIO Pharmaceuticals's valuation compare to competitors?
TRIO Pharmaceuticals is valued at $17.0M, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will TRIO Pharmaceuticals IPO?
TRIO Pharmaceuticals has not announced plans for an initial public offering. Until an IPO, investors can access TRIO Pharmaceuticals shares through secondary market platforms.